CN109568248A - 一种兽用复方透皮制剂 - Google Patents

一种兽用复方透皮制剂 Download PDF

Info

Publication number
CN109568248A
CN109568248A CN201910053930.6A CN201910053930A CN109568248A CN 109568248 A CN109568248 A CN 109568248A CN 201910053930 A CN201910053930 A CN 201910053930A CN 109568248 A CN109568248 A CN 109568248A
Authority
CN
China
Prior art keywords
transdermal agent
albendazole
ivermectin
avermectin
transdermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910053930.6A
Other languages
English (en)
Inventor
焦华
周建娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Ruanyin Technology Co Ltd
Original Assignee
Tianjin Ruanyin Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Ruanyin Technology Co Ltd filed Critical Tianjin Ruanyin Technology Co Ltd
Priority to CN201910053930.6A priority Critical patent/CN109568248A/zh
Publication of CN109568248A publication Critical patent/CN109568248A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种兽用复方透皮制剂的制备方法，主要由药物成分，溶剂，透皮剂组成。通过透皮剂的作用，能实现透皮，长效给药，克服了目前注射给药复杂，以及饲混给药不均一的不足。本方法制得的透皮剂驱虫效果显著。

Description

一种兽用复方透皮制剂
技术领域
本发明设计兽药领域，一种复方透皮剂。
背景技术
目前，兽用驱虫药主要为注射剂、口服制剂两种。注射剂应激反应比较激烈，操作不方便，尤其需要专业人员操作，并且容易造成交叉感染。与此同时，注射液大多为伊维菌素注射液，针对寄生虫种类有限，只能治疗一部分寄生虫。口服制剂一般为粉末剂型较多，搅拌不均，药物会经过肝脏的首过效应，药效明显降低。针对表皮，药物浓度很难到达有效浓度。所以一种复方、透皮的产品是解决以上难题的最佳解决方案。
发明内容
本发明目的在于提供一种复方兽用透皮剂的配方及制备方法。
一种兽用复方透皮制剂其特征是按照如下份原料组成：
伊维菌素10g、阿苯达唑200g、乙酸乙酯500ml、月桂氮卓酮40ml、乙二醇460ml。
根据所述一种兽用复方透皮制剂是按照如下方法制得：
按照处方取伊维菌素、阿苯达唑，加入乙酸乙酯，搅拌成悬浊液，依次加入月桂氮卓酮、乙二醇，摇匀即得该兽用透皮剂。
具体实施方案
实施例1
取伊维菌素10g、阿苯达唑200g、乙酸乙酯500ml、月桂氮卓酮40ml、乙二醇460ml；
将伊维菌素、阿苯达唑，放入容器，加入乙酸乙酯，搅拌成悬浊液，依次加入月桂氮卓酮、乙二醇，摇匀即得该兽用透皮剂。
实施例2
取阿维菌素10g、芬苯达唑200g、乙酸乙酯500ml、二甲基亚砜40ml、乙二醇460ml；
将阿维菌素、芬苯达唑，放入容器，加入乙酸乙酯，搅拌成悬浊液，依次加入二甲基亚砜、乙二醇，摇匀即得该兽用透皮剂。
实施例3
取伊维菌素5g、阿维菌素5g、阿苯达唑100g、芬苯达唑100g、乙酸乙酯500ml、月桂氮卓酮15ml、二甲基亚砜25ml、乙二醇460ml；
将伊维菌素、阿维菌素、阿苯达唑、芬苯达唑放入容器，加入乙酸乙酯，搅拌成悬浊液，依次加入二甲基亚砜、月桂氮卓酮、乙二醇，摇匀即得该兽用透皮剂。

Claims (6)

1.一种复方兽用透皮剂其特征在于由驱虫药物、透皮剂、溶剂组成。
2.按权利要求1中所述驱虫药物指：伊维菌素、阿维菌素、芬苯达唑、阿苯达唑中的一种或几种的混合物。
3.按权利要求1中所述透皮剂指氮酮类、醇类、亚砜类中的一类或几类混合物。
4.按权利要求3中所述透皮剂包括月桂氮酮、丙二醇、二甲基亚砜中的一种或几种的混合物。
5.按权利要求1中所述溶剂包括丙二醇、水、乙酸乙酯中的一种或几种混合物。
6.一种复方兽用透皮剂其特征在于药物成分符合以下重量比：伊维菌素：阿苯达唑=1:20，或阿维菌素：阿苯达唑=1:20，或（伊维菌素+阿维菌素）：（阿苯达唑+芬苯达唑）=1:20。
CN201910053930.6A 2019-01-23 2019-01-23 一种兽用复方透皮制剂 Pending CN109568248A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910053930.6A CN109568248A (zh) 2019-01-23 2019-01-23 一种兽用复方透皮制剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910053930.6A CN109568248A (zh) 2019-01-23 2019-01-23 一种兽用复方透皮制剂

Publications (1)

Publication Number Publication Date
CN109568248A true CN109568248A (zh) 2019-04-05

Family

ID=65916865

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910053930.6A Pending CN109568248A (zh) 2019-01-23 2019-01-23 一种兽用复方透皮制剂

Country Status (1)

Country Link
CN (1) CN109568248A (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101579309A (zh) * 2009-06-23 2009-11-18 天津必佳药业集团有限公司 家畜用抗寄生虫病伊维菌素透皮溶液及其制备方法
CN103356714A (zh) * 2013-07-21 2013-10-23 山东中牧兽药有限公司 一种兽用含阿苯达唑和伊维菌素的复方药物组合物
CN103494832A (zh) * 2013-09-29 2014-01-08 河南亚卫动物药业有限公司 一种兽用复方伊维菌素阿苯达唑透皮剂及其使用方法
CN106389456A (zh) * 2016-11-16 2017-02-15 佛山市正典生物技术有限公司 一种兽用阿苯达唑伊维菌素预混剂及其制备方法
CN107041869A (zh) * 2017-03-17 2017-08-15 河南农业大学 一种伊维菌素长效透皮吸收剂及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101579309A (zh) * 2009-06-23 2009-11-18 天津必佳药业集团有限公司 家畜用抗寄生虫病伊维菌素透皮溶液及其制备方法
CN103356714A (zh) * 2013-07-21 2013-10-23 山东中牧兽药有限公司 一种兽用含阿苯达唑和伊维菌素的复方药物组合物
CN103494832A (zh) * 2013-09-29 2014-01-08 河南亚卫动物药业有限公司 一种兽用复方伊维菌素阿苯达唑透皮剂及其使用方法
CN106389456A (zh) * 2016-11-16 2017-02-15 佛山市正典生物技术有限公司 一种兽用阿苯达唑伊维菌素预混剂及其制备方法
CN107041869A (zh) * 2017-03-17 2017-08-15 河南农业大学 一种伊维菌素长效透皮吸收剂及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
常选妞等: "兽用经皮吸收制剂的研究进展", 《兽药与饲料添加剂》 *
陈小军等: "伊维菌素制剂在动物医学中的研究进展", 《湖南畜牧兽医》 *

Similar Documents

Publication Publication Date Title
EP1299108B1 (en) A parasiticidal formulation and a method of making this formulation
EP2222168B1 (en) Solvent systems for pour-on formulations for combating parasites
TWI433691B (zh) 苯并咪唑之非水性組合物
WO2013043064A1 (en) Veterinary anthelmintic delivery system
CN113784702A (zh) 可注射药物组合物及其用途
CN109568248A (zh) 一种兽用复方透皮制剂
CN110279657A (zh) 一种氯氰碘柳胺钠注射液及其制备方法
AU2005100403B4 (en) Parasiticide Composition
RU2493825C2 (ru) Бензимидазольные антигельминтные композиции
EP4153133B1 (en) Injectable pharmaceutical compositions and uses thereof
AU2022268378A1 (en) Injectable formulation of a macrocyclic lactone and levamisole
CN100394983C (zh) 含有大豆油的多拉菌素注射液
KR101645640B1 (ko) 탈모방지, 발모촉진, 또는 양모촉진용 조성물, 및 그 제조방법
AU2006100657C4 (en) Stabilised formulation
AU2005101039B4 (en) Stable Parasiticide Composition
AU2007221747B2 (en) Medicament
Kates et al. Helminth control in grazing sheep: periodic treatment with levamisole, morantel, cambendazole, and mebendazole
AU2017200250B2 (en) A Tick Treatment
JP5774874B2 (ja) ナラ菌増殖防止剤及びナラ枯れ防止方法
BR102014031535A2 (pt) formulação farmacêutica e processo de obtenção de uma solução de uso oral contendo praziquantel e solução de uso oral contendo praziquantel assim obtida
US20160243146A1 (en) LEVIA : A New Injectable Parasiticidal Veterinary Formulation of Levamisole HCl and Ivermectin Solution.
CN107714651A (zh) 一种非班太尔脂质体及其制备方法
JPS5955822A (ja) 粘着性貼付製剤用膏体
RU2142220C1 (ru) Способ производства растениеводческой продукции и используемое в нем средство для обработки растений
RU2142219C1 (ru) Способ производства растениеводческой продукции и используемое в нем средство для обработки растений

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190405

WD01 Invention patent application deemed withdrawn after publication